SAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ -- Global plaintiffs' rights firm Hagens Berman reminds investors that the Lead Plaintiff Deadline in the securities class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) is rapidly approaching: December 15, 2025. The lawsuit alleges that MoonLake and certain executives made materially false and misleading statements regarding the clinical prospects of the company's lead and sole drug candidate, sonelokimab (SLK), causing the stock to crash nearly ...

Core Viewpoint - The lawsuit against MoonLake Immunotherapeutics alleges that the company and its executives made false statements about the clinical efficacy of their drug candidate, sonelokimab, leading to a significant stock price drop of nearly 90% following disappointing trial results [2][4]. Summary by Relevant Sections Lawsuit Allegations - The lawsuit claims that MoonLake misled investors by asserting that the unique Nanobody structure of sonelokimab would provide superior clinical outcomes compared to traditional monoclonal antibodies, specifically against the FDA-approved BIMZELX [3]. Stock Performance - Following the announcement of the VELA-2 trial results, which failed to meet its primary endpoint and demonstrated inferior efficacy, MoonLake's stock plummeted from $61.99 to $6.24, representing a 90% loss [4]. Investor Actions - Investors who purchased MoonLake stock between March 10, 2024, and September 29, 2025, and experienced significant losses are encouraged to contact Hagens Berman to explore legal options and the possibility of becoming the Lead Plaintiff [5].

Core Viewpoint - The lawsuit against MoonLake Immunotherapeutics alleges that the company and its executives made false statements about the clinical efficacy of their drug candidate, sonelokimab, leading to a significant stock price drop of nearly 90% following disappointing trial results [2][3][4]. Summary by Sections Lawsuit Details - The lawsuit claims that MoonLake's assertions regarding the superiority of its Nanobody technology were misleading, particularly in comparison to the FDA-approved competitor BIMZELX [3]. - The stock price plummeted from $61.99 to $6.24, representing a 90% loss, after the VELA-2 trial failed to meet its primary endpoint and demonstrated inferior efficacy [4]. Timeline and Key Information - Class Period: March 10, 2024 – September 29, 2025 - Lead Plaintiff Deadline: December 15, 2025 - Significant Stock Drop: 90% loss on September 29, 2025, due to failed trial results [4]. Next Steps for Investors - Investors who purchased MoonLake stock during the specified class period and incurred substantial losses are encouraged to contact Hagens Berman to explore legal options and potential appointment as Lead Plaintiff [5]. About Hagens Berman - Hagens Berman is a global plaintiffs' rights firm that focuses on corporate accountability and has secured over $2.9 billion for clients in similar cases [7].

Issuer MoonLake Immunotherapeutics (MLTX) Class Period March 10, 2024 – September 29, 2025 Lead Plaintiff Deadline December 15, 2025 Stock Drop Event Stock fell from $61.99 to $6.24 (a 90% loss) on September 29, 2025, after VELA-2 trial failed its primary endpoint and efficacy was shown to be inferior to a competitor. Next Steps for MoonLake (MLTX) Investors: SAN FRANCISCO, Dec. 12, 2025 /PRNewswire/ -- Global plaintiffs' rights firm Hagens Berman reminds investors that the Lead Plaintiff Deadline in the se ...

SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Global plaintiffs' rights firm Hagens Berman reminds investors that the Lead Plaintiff Deadline in the securities class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) is rapidly approaching: December 15, 2025. The lawsuit alleges that MoonLake and certain executives made materially false and misleading statements regarding the clinical prospects of the company’s lead and sole drug candidate, sonelokimab (SLK), causing the stock to crash nea ...

Financial Data and Key Metrics Changes - The company raised approximately CHF 750 million through equity since going public in 2022 and recently announced a non-dilutive facility of about $500 million [7][26] - The dropout rates in clinical trials remain low, operating in single-digit percentages, which is a characteristic of the sonelokumab (SLK) trials [22][44] Business Line Data and Key Metrics Changes - The company is focused on two main areas: dermatology and rheumatology, with multiple ongoing trials including Phase III for hidradenitis suppurativa (HS) and Phase II for palmo-plantar pustulosis (PPP) [15][18] - The VALOR program for HS has completed recruitment faster than competitors, with a primary endpoint readout expected in Q3 [20][52] Market Data and Key Metrics Changes - The market for HS is characterized by a high prevalence of approximately 2.5 million patients in the U.S., with a significant portion being untreated [82][89] - The biologics share in HS treatment remains low, indicating a large opportunity for growth as many patients are still naive to biologic therapies [88][92] Company Strategy and Development Direction - The company aims to position sonelokumab as the gold standard in HS treatment, focusing on achieving a delta in high score 75 that starts with a two [66][68] - The strategy includes leveraging the unique characteristics of sonelokumab, such as its low immunogenicity and convenient dosing schedule, to differentiate from competitors [76][71] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming data readout and the potential for sonelokumab to outperform competitors based on the robust clinical trial design and patient characteristics [52][45] - The company highlighted the importance of addressing unmet needs in the HS market and the potential for significant market share due to limited competition [93][94] Other Important Information - The company has a strong pipeline with a mix of Phase II and Phase III trials, indicating a commitment to expanding its product offerings [16][18] - The competitive landscape is described as limited, with few products available that can effectively compete with sonelokumab [73][94] Q&A Session Summary Question: What is the expected timeline for the VALOR program data readout? - The primary endpoint data for the VALOR program is expected to be shared around September, following quality control processes after the completion of recruitment [52][51] Question: How does the company plan to differentiate sonelokumab from competitors? - The company aims to demonstrate superior efficacy and a more convenient dosing regimen compared to competitors, which is crucial for gaining market acceptance [66][71]